Pfizer India
- All
- News
- Videos
-
2 Indian-Origin People Charged In US With Insider Trading With Pfizer Covid-19 Medicine
In a parallel action, the US Attorney's Office for the Southern District of New York also announced criminal charges against the duo.
-
Pfizer Names Meenakshi Nevatia As Managing Director
Drug maker Pfizer Ltd on Thursday said it has appointed Meenakshi Nevatia as managing director for a period of five years with effect from April 3, 2023.
-
Government Blocked Pfizer's Covid Vaccine, Claims KCR In New Attack
Telangana Chief Minister K Chandrashekar Rao has alleged that the Central government did everything possible to "forcefully" prevent import of COVID-19 vaccines from Pfizer, especially when people were ready to get the best vaccine.
-
Made In India Covid Vaccines Better Than Pfizer, Moderna, Says Adar Poonawalla: Report
Serum Institute of India (SII) CEO Adar Poonawalla today claimed that "Made in India" COVID-19 vaccines have provided more protection against the coronavirus infection than mRNA vaccines like Pfizer and Moderna.
-
US Authorizes Pfizer COVID-19 Booster Shot For Children As Young As 12
US health authorities on Monday approved Pfizer's Covid-19 booster shot for children as young as 12, and reduced the wait time between initial vaccination and an extra dose from six months to five, for all ages.
-
Booster Dose Of 6 Covid Vaccines Safe, Increases Immunity: Lancet Study
Six different COVID-19 boosters are safe and elicit strong immune response in people who have previously received a two-dose course of AstraZeneca or Pfizer vaccines, according to a study published in The Lancet journal.
-
Dr Reddy's Open To Making Pfizer Covid Pill
Dr Reddy's Laboratories, one of a handful of Indian drug companies licensed to make a new COVID-19 pill developed by Merck, said on Monday it was open to making a similar pill from Pfizer, thought to be even more effective.
-
Game-Changing Made-In-India Anti-Covid Pills Could Be Cleared For Use In Days
Emergency Use Authorisation for the Merck drug Molnupiravir -- an oral antiviral medicine for the treatment of mild-to-moderate COVID-19 -- is likely "within days", Dr Ram Vishwakarma, Chairman of the Covid Strategy Group, CSIR, told NDTV today.
-
Covid Poses Higher Risk Of Rare Brain Conditions Than Vaccines: Oxford-Led Study
COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.
-
Pfizer Vaccine Highly Effective Against COVID-19 Hospitalisations For 6 Months: Lancet Study
Two doses of the Pfizer COVID-19 vaccine are 90 per cent effective against hospitalisation from the disease for all variants, including Delta, for at least six months, according to a study published in The Lancet journal on Tuesday.
-
Government Won't Buy Pfizer, Moderna Shots As Local Output Jumps: Report
India will not buy COVID-19 shots from Pfizer/BioNTech and Moderna, three government sources told Reuters, mainly because domestic output of more affordable and easier-to-store vaccines has jumped.
-
UK Schoolchildren Aged 12-15 Years To Be Offered Covid Vaccine First Dose
Schoolchildren aged between 12 and 15 years will be offered a first dose of the Pfizer/BioNTech COVID-19 vaccine starting next week, the UK government has announced after the country's Chief Medical Officers gave their go-ahead for the jabs for young
-
80% Covid Immunity Lost In 6 Months In Some After Pfizer Jab: US Study
COVID-19 antibodies produced by the Pfizer vaccine decreased more than 80 per cent in senior nursing home residents and their caregivers six months after receiving their second dose, a US study has found.
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
-
"Not Even Enough For...": Vaccine Panel Chief On Pfizer, Moderna Offers
All US-based vaccine makers are insisting on indemnity and liability clauses and Indias reluctance to meet them is slowing down their entry in the market, NK Arora, head of the governments vaccine panel told NDTV yesterday.
-
2 Indian-Origin People Charged In US With Insider Trading With Pfizer Covid-19 Medicine
In a parallel action, the US Attorney's Office for the Southern District of New York also announced criminal charges against the duo.
-
Pfizer Names Meenakshi Nevatia As Managing Director
Drug maker Pfizer Ltd on Thursday said it has appointed Meenakshi Nevatia as managing director for a period of five years with effect from April 3, 2023.
-
Government Blocked Pfizer's Covid Vaccine, Claims KCR In New Attack
Telangana Chief Minister K Chandrashekar Rao has alleged that the Central government did everything possible to "forcefully" prevent import of COVID-19 vaccines from Pfizer, especially when people were ready to get the best vaccine.
-
Made In India Covid Vaccines Better Than Pfizer, Moderna, Says Adar Poonawalla: Report
Serum Institute of India (SII) CEO Adar Poonawalla today claimed that "Made in India" COVID-19 vaccines have provided more protection against the coronavirus infection than mRNA vaccines like Pfizer and Moderna.
-
US Authorizes Pfizer COVID-19 Booster Shot For Children As Young As 12
US health authorities on Monday approved Pfizer's Covid-19 booster shot for children as young as 12, and reduced the wait time between initial vaccination and an extra dose from six months to five, for all ages.
-
Booster Dose Of 6 Covid Vaccines Safe, Increases Immunity: Lancet Study
Six different COVID-19 boosters are safe and elicit strong immune response in people who have previously received a two-dose course of AstraZeneca or Pfizer vaccines, according to a study published in The Lancet journal.
-
Dr Reddy's Open To Making Pfizer Covid Pill
Dr Reddy's Laboratories, one of a handful of Indian drug companies licensed to make a new COVID-19 pill developed by Merck, said on Monday it was open to making a similar pill from Pfizer, thought to be even more effective.
-
Game-Changing Made-In-India Anti-Covid Pills Could Be Cleared For Use In Days
Emergency Use Authorisation for the Merck drug Molnupiravir -- an oral antiviral medicine for the treatment of mild-to-moderate COVID-19 -- is likely "within days", Dr Ram Vishwakarma, Chairman of the Covid Strategy Group, CSIR, told NDTV today.
-
Covid Poses Higher Risk Of Rare Brain Conditions Than Vaccines: Oxford-Led Study
COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.
-
Pfizer Vaccine Highly Effective Against COVID-19 Hospitalisations For 6 Months: Lancet Study
Two doses of the Pfizer COVID-19 vaccine are 90 per cent effective against hospitalisation from the disease for all variants, including Delta, for at least six months, according to a study published in The Lancet journal on Tuesday.
-
Government Won't Buy Pfizer, Moderna Shots As Local Output Jumps: Report
India will not buy COVID-19 shots from Pfizer/BioNTech and Moderna, three government sources told Reuters, mainly because domestic output of more affordable and easier-to-store vaccines has jumped.
-
UK Schoolchildren Aged 12-15 Years To Be Offered Covid Vaccine First Dose
Schoolchildren aged between 12 and 15 years will be offered a first dose of the Pfizer/BioNTech COVID-19 vaccine starting next week, the UK government has announced after the country's Chief Medical Officers gave their go-ahead for the jabs for young
-
80% Covid Immunity Lost In 6 Months In Some After Pfizer Jab: US Study
COVID-19 antibodies produced by the Pfizer vaccine decreased more than 80 per cent in senior nursing home residents and their caregivers six months after receiving their second dose, a US study has found.
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
-
"Not Even Enough For...": Vaccine Panel Chief On Pfizer, Moderna Offers
All US-based vaccine makers are insisting on indemnity and liability clauses and Indias reluctance to meet them is slowing down their entry in the market, NK Arora, head of the governments vaccine panel told NDTV yesterday.
